Abstract We investigated the management and treatment of pregnant opioid users by Drug Treatment Services in England and Wales. A postal survey was conducted among 223 Community Drug Treatment Services (CDTS) across England and Wales. Sixty-six percent CDTS responded (n=154/233) to the survey. Over half CDTS (55.3 %) provided a maintenance methadone dose lower than that recommended for non-pregnant drug users. There were significant variations on how professionals approached the management of pregnant opioid users. CDTS with an addiction specialist were significantly more likely (p<0.01) to advocate high doses of methadone whereas those with a midwife, obstetrician or social worker involved were more likely (p<0.05) to suggest low dose methadone and/or detoxification. Service provision for pregnant opioid users is reliable and comprehensive but there is still variability in some aspects of the treatment received and the way in which methadone is prescribed is not always optimal.
of this complex group. However, methadone maintenance treatment has been the consensus adopted by the United States (Centre for Substance Abuse Treatment 2009), Australia (e.g. New South Wales Department of Health 2006), and the UK (Department of Health (England) and the Devolved Administrations 2007) for the management of pregnant opioid dependent women. Nevertheless the benefits of methadone for the treatment of this group has remained controversial (McGlone et al. 2008) . Research pertaining to the effectiveness of methadone during pregnancy has been wide ranging but rarely systematic (Jones et al. 2008) . Ethical considerations coupled with cost have severely restricted the number of investigations that adequately covers the pre-, peri-and post-natal periods (Wolff et al. 2005 ). There have also been conflicting findings on fetal, neonatal and maternal outcomes of methadone maintained pregnant opioid users (DePetrillo and Rice 1995; Drozdick et al. 2002; Hagopian et al. 1996; Kempley 1995; Winklbaur et al. 2008) . Arguments, supporting either high dose methadone during pregnancy (to avoid opioid withdrawal and fetal distress or relapse to illicit drug use), or challenging the benefits of this strategy by advocating low dose pharmacotherapy or detoxification (to reduce the occurrence of neonatal withdrawal), continue to be made (Nunn et al. 2009; Maas et al. 1990 ).
The UK Government Home Office, Professional and Non-Professional bodies, the Royal College of General Practitioners (Ford et al. 2005) And although the more recent National Institute for Health and Clinical Excellence (NICE) guidelines on pregnancy (National Institute for Health and Clinical Excellence (NICE) 2010) addressed many of the issues surrounding the provision of services for this complex group, its remit did not include pharmacotherapy for opioid dependence during pregnancy.
There is international consensus on the effectiveness of fixed daily doses of between 60 and 120 mg methadone for dependent drug users (Faggiano et al. 2003) , however, there is no such accord for those who are pregnant. This creates an unnecessary ambiguity for the clinician who faces a dosing dilemma; the benefits of high dose methadone against its possible association with a neonatal abstinence syndrome (NAS). Little has been recorded in England and Wales about prescribing practices for opioid dependent addicts who become pregnant. In light of the absence of information about this vulnerable population we investigated the provision of services for pregnant opioid dependent women and in particular how Community Drug Treatment Services (CDTS) address the issue of pharmacotherapy.
Method
A list of 387 different drug treatment services across England and Wales was identified from Drugscope's helpfinder (www.drugscope.org.uk/resources/helpfinder-accessed October 2006). Drug treatment services in the UK are predominantly provided in the form of the Community Drug Treatment Service (CDTS). These offer a range of services, which varies from psychosocial interventions to substitute prescribing, to those affected by drug misuse. Drug services can be based either in the community or be part of other pathways e.g. detoxification (residential rehabilitation) or criminal justice (prison services). For the purpose of this study only those CDTS that provided prescribing services were included. Services for young people, rehabilitation centres, special population services and prison 
Statistical Analysis
Descriptive and chi square modelling was used for the first stage of the analysis and chi square testing and one by one correlational techniques used for comparing binary variables. Difference between CDTS was also assessed for statistical significance using Mann-Whitney U-test or Kruskal-Wallis as appropriate. Logistic regression models were used to determine factors that influenced service provision (service demographics, staff profession, number of clients and prescribing policy etc.). In contingency tables larger than 2×2, a chisquare test was used if fewer than 20 % of the expected frequencies were less than five and no expected frequency was less than one. Where this requirement was not met the recommendation of Siegel and Castellan (Siegel and Castellan 1988) and others (Bland 1987; Kirkwood 1988 ) was followed and, wherever appropriate, categories were combined to reduce the number of cells to a 2×2 table thus increasing the expected frequencies.
Results
Sixty-six percent of CDTS managers (n=154/233) responded to the survey representing 8 key regions in England & Wales (see Table 1 ). Seventy three percent of CDTS reported treating ≤10 pregnant drug users at any one time (40 % treating ≤5). At the time of the survey the remaining 27 % CDTS reported having >10 pregnant opioid addicts in their service.
Service Provision
A considerable proportion of pregnant drug users were already known to CDTS and/or presented during the first trimester of pregnancy (72.5 %). Only a small minority (7.4 %) reported referrals as a consequence of a late presentation of pregnancy. Most women The response rates represent the proportion of respondents from the total of community drug treatment services (CDTS) identified in each region (81.2 %) self-referred although managers also reported referrals from GPs (73.4 %), antenatal clinics (68.8 %), social services (57.8 %) and the criminal justice/probation service.
Service Structure
The composition of CDTS varied but predominantly comprised a prescribing doctor (96 %), and drug and alcohol nurses (89.5 %); many CDTS reported having a pregnancy addiction specialist (60 %), who was often a drug and alcohol nurse (77.2 %). Sixty-four CDTS (42 %) reported having a specialist clinic for pregnant drug users In addition, almost half CDTS had a drug counsellor (48.4 %) and/or a drug worker (43 %). Clinical Psychologists (CP) and Community Psychiatric Nurses (CPN) were also reported as part of the team (32.0 % and 31.4 %, respectively). Service managers reported having close links with community midwives (83.0 %), obstetricians (65.4 %) and social services (65.4 %).
Methadone
Methadone pharmacotherapy was the treatment of choice (97.4 %, 148/152) for pregnant women whilst buprenorphine (67.8 %) was also commonly prescribed but only 35 % of CDTS offered 'maintenance' dosing to pregnant women, and 10.6 % stabilization followed by detoxification (see Fig. 1 Fig. 1 Percentage of community drug treatment services (CDTS, N=154) offering different treatment options to pregnant opioid users. ID inpatient detoxification; CD community detoxification; BM buprenorphine maintenance; BSD buprenorphine stabilisation following by detoxification; MM methadone maintenance; MML methadone maintenance low dose; MSD methadone stabilisation followed by detoxification One third of managers (33.6 %) reported that their service had a 'high-dose' policy for pregnant women: reporting a total mean maximal dose of 138 mg (SD ± 35.7 mg) methadone/day. CDTS that shared care with non-specialist midwives reported prescribing a significantly (P<014) lower maximum daily dose of methadone (median 120 mg/day). Most CDTS (93.2 %) reported that they would increase the daily dose of methadone if a pregnant woman complained of opioid withdrawal symptoms during the third trimester, with 91.4 % prescribing increments of between 5 and 10 mg methadone/day. Managers reported that CDTS also recommended splitting the daily methadone dose (61.9 %); and some advocated alternative therapies (13.6 %, 20/147). A small number advised 'coping' with opioid withdrawal symptoms rather than offer an intervention (6.1 %, 9/147).
Many CDTS (65.5 %) also employed gradual methadone dosage reduction during pregnancy. A policy of methadone stabilisation followed by detoxification was reported by 34.4 % of CDTS managers. The odds of receiving this dosage regime was significantly greater (OR 3.16 v OR 3.19) were involved in treatment planning. Prescribing decisions were also influenced by concern about the neonatal abstinence syndrome (NAS). Of those services (41 %) that believed the onset and severity of NAS were associated with methadone dose, the majority (96.5 %) had a policy of prescribing <30 mg day. Services that had an in-house policy for pregnant women were significantly more likely [X2 (1, N=134)=3.91, P<048, Phi=−174] to report that there was no association between methadone dose and NAS and prescribed higher doses.
Community-based opioid detoxification was offered by 23. ] and explained between 6.3 % (Cos and Snell square) and 8.6 % (Nagelkerke R squared) of the variance in flexibility with methadone dosing and correctly classified 67.3 % of managers responses. However, only the variable 'neonatologist' made a unique statistically significant contribution to treatment and when a neonatologist was involved CDTS were 2.28 times more likely to offer inpatient detoxification.
Buprenorphine
Although buprenorphine was commonly prescribed (67.8 %) for pregnant opioid dependent women, only 35 % of CDTS offered 'maintenance' dosing, and even fewer (10.6 %) stabilization followed by detoxification.
Benzodiazepines
Many CDTS (60 %) reported prescribing benzodiazepines to pregnant drug users. There was a significant association (P<027) between having an in-house clinic specifically for pregnant women and prescribing benzodiazepines. CDTS with a pregnancy addiction specialist were twice (OR=2.18) as likely to prescribe benzodiazepines as those without an appointed in-house specialist service [X 2 (1, n=149)=6.84 P<027, Cramer's V=0.18].
Discussion
This is the first study to investigate the treatment provision, by CDTS, offered to pregnant opioid users in England and Wales. Service managers reported that CDTS were multidisciplinary in nature and heterogeneous in composition. Integrated care services such as those reported here are advocated as an effective model of care in the UK (National Institute for Health and Clinical Excellence (NICE) 2010; Becker and Duffy 2002) , and indeed practice in many areas according to the number of healthcare professionals working together would appear successfully delivered with the majority of pregnant opioid users accessing CDTS and antenatal services during their first trimester. Overall CDTS appeared to have the necessary competences to provide a service for this complex population. MMT was the treatment of choice for the majority of CDTS in line with the UK National guidelines. Methadone dosing at the time was recommended as "low dose maintenance for pregnant opioid users" (pp 82, 1999) (Department of Health (England) and the Devolved Administrations 1999), which was amended to "maintenance at a dose that stops or minimises illicit use' (pp 81 7.4.7.1; 2007) (Department of Health (England) and the Devolved Administrations 2007) soon after this study. Results suggest that the majority of CDTS followed recommendations by the National guidelines published at the time of the survey by recommending a low methadone maintenance dose. However, practice remained varied in England and Wales with a considerable proportion of CDTS advocating stabilisation followed by detoxification. Furthermore, this research indicates that in most cases pregnant opioid users were treated with sub-therapeutic methadone doses (55.3 % of CDTS prescribed fixed daily dose ≤50 mg methadone/day) at odds with the scientific evidence at the time which suggested doses between 50 and 150 mg per day 'with the occasional need for even higher doses in the third trimester' (Drozdick et al. 2002) . Dosing strategy was largely dependent upon the professional profile of the treatment service. For instance, the role of both the neonatologist and the social worker was significant [.X 2 (2, N=150)=9.72, P<008] and classified 67.3 % of managers responses. The lack of National clinical guidelines since 1999 at the time of the study and new emergent evidence may explain the variability of approach in the management of this complex group. However, this survey did not assess participants understanding and knowledge of the National guidelines published at that time.
Although treatment practices have been investigated internationally (Brady and Ashley 2005; Miles et al. 2010; Wolff et al. 2005) , little has been reported about community-based services for pregnant women in the United Kingdom. The Advisory Council on the Misuse of Drugs (ACMD) (Advisory Council on the Misuse of Drugs 2003) described the provision of services for this complex group in 2003 however, only 20 % of respondents to that survey were prescribing services. This CDTS survey was conducted on a nationally representative sample where sampling error was minimised by selecting only community-based services that provided substitute pharmacotherapy. In addition, a response rate of 66 % was achieved overall which is above the response rate considered acceptable for self-completion questionnaires (Sitzia and Wood 1998) . Selection bias may have been present amongst those service managers who chose to take part but this was thought unlikely since this study substantiates work conducted on individual clinics in the field. The survey was however conducted just prior to the publication of the 2007 National guidelines (Department of Health (England) and the Devolved Administrations 2007), although these were not significantly different from those published in 1999 (Department of Health (England) and the Devolved Administrations 1999).
Even though methadone detoxification during pregnancy has remained controversial, this approach was frequently reported by CDTS managers. Both inpatient (offered by 37 % CDTS) and outpatient (24 % CDTS) detoxification and detoxification following stabilisation (34 % CDTS) were reported. Opioid detoxification has been contra-indicated in both the first trimester of pregnancy because of the risk of miscarriage and in the last trimester because of the possibility of precipitating pre-term labour, fetal distress, and even stillbirth (Department of Health (England) and the Devolved Administrations 2007). However, Young (Young 2007) revealed that the underlying evidence was tentative at best and based on two case studies that had low scientific power (n=1) and no controls (Rementeria and Nunag 1973; Zuspan et al. 1975) . The Royal College of General Practitioners', using evidence from a comparison of two self-selected Scottish groups (Hepburn 1997) , suggest that methadone detoxification can be carried out 'at any speed and at any stage' during pregnancy (Ford et al. 2005) . Others highlight nevertheless the poor maternal treatment outcomes observed following opioid detoxification, such as the high rate of relapse back to illicit drug use (Kashiwagi et al. 2005) , which has been widely observed to be detrimental to neonatal outcomes (Hulse et al. 1997; Unger et al. 2011) . In this survey the likelihood of a CDTS recommending inpatient detoxification was doubled (0R=2.28) when neonatologists, were involved in patient care. The rationale for this treatment approach was not reported but it may have been that neonatologists like other clinicians, sought to err on the side of caution and advocate detoxification to avert the fear of fetal sedation or NAS. Variability in the way that national drug policy is interpreted was evident from our respondents, a finding that substantiates qualitative research in the UK (Klee 2002) , which reports that conflicting advice is given to pregnant opioid users by different healthcare professionals. Further work is required to establish the effectiveness of methadone detoxification for this population.
High-dose MMT during pregnancy, on the other hand, has been associated with positive outcomes such as 'normal' gestational birth weight and head circumference (Hagopian et al. 1996; Hulse et al. 1997; Wittmann and Segal 1991) , reduced neonatal complications and a shorter period of hospitalisation (Igboekwu and Wolff 2010) . Indeed leading researchers in North America advocate a policy of high-dose therapy for pregnant opioid users (Drozdick et al. 2002) . In the UK, the 2007 NICE guidelines: 'Methadone and buprenorphine for the management of opioid dependence' (National Institute for Health and Clinical Excellence (NICE) 2007), recommended fixed daily dosing of 60 to 110 mg methadone as optimal therapy for opioid dependent addicts. Evidence from North America suggests that these dosage regimes could be safely applied to pregnant women in the UK, who demonstrate appropriate severity of dependence, yet only a third of our CDTS had a high-dose MMT policy. Decisions concerning high doses were significantly more likely when healthcare professionals with specialist knowledge such as pregnancy addiction specialists and addiction counsellors (OR 2.61 and OR 2.19, P<008, respectively) were involved, suggesting that expertise and training is important for the care of these women. There was greater consistency of care concerning withdrawal symptom complaints during the last trimester of pregnancy with 93 % CDTS advising pharmacological intervention and/or division of the daily dose However, practice elsewhere has not followed this policy and in Scotland, with multiple agency support, women reportedly managed dosage reductions in the later stages of pregnancy, without clinical intervention (Hepburn 2002) .
More systematic work is required to familiarise healthcare professionals, policy makers and commissioners with the evidence that demonstrates the benefit of high-dose of MMT during pregnancy. Keeping drug addicts in treatment is accepted by the UK National Audit Office as being cost-effective; saving £1 for every £2.50 spent on treatment (National Audit Office 2010; Barnard et al. 2009 ). Furthermore, in the interests of maternal and infant welfare definitive evidence must be gathered that abstinence is sustainable in the post natal period following detoxification treatment. Although prescribing decisions are, by their nature individually formed, advocates of detoxification may overestimate the ability of the newly abstinent mother to cope with child rearing as well and the process of recovery from a chronic relapsing condition. Research in the British context of the community-based drug treatment service should be urgently commissioned to clarify dosing strategies for pregnant addicts, replicating North American work if necessary.
Further consideration also needs to be given to the influence of different disciplines in prescribing decisions. More stringent efforts should be made to ensure that all healthcare professionals involved in the care of pregnant opioid dependent women are aware and work within the national clinical guidelines for substance misuse and dependence. This is because National clinical guidelines are produced by experts in the field based on scientific evidence and recommend best practice. Dissemination of the National clinical guidelines to all those healthcare professionals' involved is therefore important. The many conflicting messages that remain for those charged with the care of pregnant opioid users may be due to a lack of dissemination of the evidence-based information: a need for consensus on how to manage this population is urgently required.
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